Advanced Accelerator Applications

Advanced Accelerator Applications is an innovative radiopharmaceutical company developing, producing and commercializing molecular nuclear medicine theragnostics.

AAA is at the forefront of developing predictive, preventive and personalized tools and procedures that have the potential to radically transform healthcare.

AAA is developing a pipeline of theragnostic pairings for oncology indications. The company’s theragnostic platform involves radiolabeling a targeting molecule with either gallium Ga 68 for diagnostic use, or lutetium Lu 177 for therapy.

Recent Portfolios